Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.

2.50
Hdl Handle:
http://hdl.handle.net/10541/74815
Title:
Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.
Authors:
Lapointe, R; Létourneau, R; Steward, William P; Hawkins, Robert E; Batist, G; Vincent, M; Whittom, R; Eatock, Martin M; Jolivet, Jacques; Moore, M
Abstract:
BACKGROUND: Troxacitabine (Troxatyl) is a novel L-enantiomer nucleoside analog with activity in pancreatic cancer xenograft models. PATIENTS AND METHODS: Troxacitabine 1.5 mg/m(2) was administered by 30-min infusions daily x5 every 4 weeks to 54 patients with advanced pancreatic cancer. Patients were evaluated for objective tumor response, time to tumor progression (TTP), changes in tumor marker CA 19-9, survival, safety, pain, analgesic consumption, Karnofsky performance status and weight change. RESULTS: Median TTP was 3.5 months (95% CI 2.0-3.8), median survival 5.6 months (95% CI 4.9-7.4), and the 1 year survival rate 19%. Best responses were stable disease in 24 patients with eight patients having stable disease for at least 6 months (15%). A 50% or greater decrease in CA 19-9 was seen in seven of 44 assessed patients (16%). Grade 3 and 4 neutropenia were observed in 37% and 30% of patients with one episode of febrile neutropenia. The most common drug-related non-hematological toxic effects reported were cutaneous, with 22% and 6% of patients reporting grade 2 and 3 skin rash, respectively and 4% grade 2 hand-foot syndrome. CONCLUSION: Troxacitabine administered by a bolus daily x5 monthly regimen has modest activity in advanced pancreatic adenocarcinoma.
Affiliation:
Centre Hospitalier de l'Université de Montréal, St-Luc Hospital, Montreal, Quebec, Canada.
Citation:
Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors. 2005, 16 (2):289-93 Ann. Oncol.
Journal:
Annals of Oncology
Issue Date:
Feb-2005
URI:
http://hdl.handle.net/10541/74815
DOI:
10.1093/annonc/mdi061
PubMed ID:
15668286
Type:
Article
Language:
de
ISSN:
0923-7534
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorLapointe, R-
dc.contributor.authorLétourneau, R-
dc.contributor.authorSteward, William P-
dc.contributor.authorHawkins, Robert E-
dc.contributor.authorBatist, G-
dc.contributor.authorVincent, M-
dc.contributor.authorWhittom, R-
dc.contributor.authorEatock, Martin M-
dc.contributor.authorJolivet, Jacques-
dc.contributor.authorMoore, M-
dc.date.accessioned2009-07-21T16:36:42Z-
dc.date.available2009-07-21T16:36:42Z-
dc.date.issued2005-02-
dc.identifier.citationPhase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors. 2005, 16 (2):289-93 Ann. Oncol.en
dc.identifier.issn0923-7534-
dc.identifier.pmid15668286-
dc.identifier.doi10.1093/annonc/mdi061-
dc.identifier.urihttp://hdl.handle.net/10541/74815-
dc.description.abstractBACKGROUND: Troxacitabine (Troxatyl) is a novel L-enantiomer nucleoside analog with activity in pancreatic cancer xenograft models. PATIENTS AND METHODS: Troxacitabine 1.5 mg/m(2) was administered by 30-min infusions daily x5 every 4 weeks to 54 patients with advanced pancreatic cancer. Patients were evaluated for objective tumor response, time to tumor progression (TTP), changes in tumor marker CA 19-9, survival, safety, pain, analgesic consumption, Karnofsky performance status and weight change. RESULTS: Median TTP was 3.5 months (95% CI 2.0-3.8), median survival 5.6 months (95% CI 4.9-7.4), and the 1 year survival rate 19%. Best responses were stable disease in 24 patients with eight patients having stable disease for at least 6 months (15%). A 50% or greater decrease in CA 19-9 was seen in seven of 44 assessed patients (16%). Grade 3 and 4 neutropenia were observed in 37% and 30% of patients with one episode of febrile neutropenia. The most common drug-related non-hematological toxic effects reported were cutaneous, with 22% and 6% of patients reporting grade 2 and 3 skin rash, respectively and 4% grade 2 hand-foot syndrome. CONCLUSION: Troxacitabine administered by a bolus daily x5 monthly regimen has modest activity in advanced pancreatic adenocarcinoma.en
dc.language.isodeen
dc.subjectPancreatic Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBody Weight-
dc.subject.meshCytosine-
dc.subject.meshDioxolanes-
dc.subject.meshDisease Progression-
dc.subject.meshFemale-
dc.subject.meshHealth Status-
dc.subject.meshHumans-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPain-
dc.subject.meshPancreatic Neoplasms-
dc.subject.meshSurvival Analysis-
dc.subject.meshTreatment Outcome-
dc.titlePhase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.de
dc.typeArticleen
dc.contributor.departmentCentre Hospitalier de l'Université de Montréal, St-Luc Hospital, Montreal, Quebec, Canada.en
dc.identifier.journalAnnals of Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.